Concepts (198)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 36 | 2024 | 128 | 6.440 |
Why?
|
| Prostatic Neoplasms | 7 | 2023 | 29 | 2.530 |
Why?
|
| Neoplasms | 8 | 2023 | 141 | 1.860 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 31 | 1.400 |
Why?
|
| Neoplasm Staging | 8 | 2023 | 48 | 1.320 |
Why?
|
| South Africa | 42 | 2023 | 7312 | 1.200 |
Why?
|
| Prostate-Specific Antigen | 2 | 2023 | 10 | 1.110 |
Why?
|
| Humans | 55 | 2024 | 14077 | 1.080 |
Why?
|
| HIV Infections | 13 | 2023 | 4946 | 1.070 |
Why?
|
| Healthcare Disparities | 3 | 2024 | 41 | 0.910 |
Why?
|
| Androgen Antagonists | 1 | 2023 | 2 | 0.910 |
Why?
|
| Female | 42 | 2024 | 8751 | 0.900 |
Why?
|
| Middle Aged | 26 | 2024 | 3425 | 0.860 |
Why?
|
| Noncommunicable Diseases | 1 | 2023 | 75 | 0.810 |
Why?
|
| Aged | 15 | 2024 | 1650 | 0.730 |
Why?
|
| Tobacco Use Cessation | 1 | 2020 | 3 | 0.710 |
Why?
|
| Attitude to Health | 1 | 2020 | 56 | 0.680 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 37 | 0.680 |
Why?
|
| Receptor, ErbB-2 | 7 | 2023 | 17 | 0.630 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 230 | 0.600 |
Why?
|
| Age of Onset | 1 | 2018 | 32 | 0.600 |
Why?
|
| Prospective Studies | 11 | 2024 | 1131 | 0.540 |
Why?
|
| Terminal Care | 4 | 2020 | 34 | 0.510 |
Why?
|
| Male | 15 | 2023 | 6489 | 0.510 |
Why?
|
| Adult | 18 | 2024 | 5664 | 0.500 |
Why?
|
| Case-Control Studies | 7 | 2023 | 464 | 0.430 |
Why?
|
| Receptors, Progesterone | 5 | 2023 | 14 | 0.390 |
Why?
|
| Cohort Studies | 10 | 2023 | 939 | 0.380 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 449 | 0.380 |
Why?
|
| Diet | 3 | 2021 | 108 | 0.370 |
Why?
|
| Terminally Ill | 3 | 2019 | 21 | 0.350 |
Why?
|
| Receptors, Estrogen | 4 | 2021 | 14 | 0.340 |
Why?
|
| Diabetes Mellitus | 2 | 2023 | 137 | 0.330 |
Why?
|
| Mastectomy | 2 | 2020 | 10 | 0.320 |
Why?
|
| Carcinoma | 2 | 2018 | 9 | 0.310 |
Why?
|
| Neoadjuvant Therapy | 4 | 2023 | 14 | 0.310 |
Why?
|
| Ki-67 Antigen | 3 | 2023 | 13 | 0.280 |
Why?
|
| Risk Factors | 8 | 2022 | 1431 | 0.280 |
Why?
|
| Hypertension | 2 | 2023 | 397 | 0.280 |
Why?
|
| Hospitals, Public | 2 | 2018 | 44 | 0.270 |
Why?
|
| Chronic Disease | 2 | 2023 | 100 | 0.260 |
Why?
|
| Developing Countries | 3 | 2024 | 385 | 0.260 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2023 | 168 | 0.260 |
Why?
|
| Prevalence | 4 | 2022 | 1149 | 0.260 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 32 | 0.260 |
Why?
|
| Multimorbidity | 2 | 2023 | 42 | 0.250 |
Why?
|
| Urban Population | 3 | 2024 | 246 | 0.240 |
Why?
|
| Immunohistochemistry | 2 | 2023 | 26 | 0.240 |
Why?
|
| Palliative Care | 3 | 2020 | 50 | 0.240 |
Why?
|
| Genome-Wide Association Study | 2 | 2022 | 100 | 0.230 |
Why?
|
| Medical Assistance | 1 | 2023 | 8 | 0.230 |
Why?
|
| Feeding Behavior | 2 | 2021 | 59 | 0.230 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2024 | 32 | 0.220 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2023 | 4 | 0.220 |
Why?
|
| Leukopenia | 1 | 2023 | 4 | 0.220 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2023 | 103 | 0.220 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 8 | 0.220 |
Why?
|
| Papillomavirus Infections | 1 | 2024 | 72 | 0.210 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2023 | 9 | 0.210 |
Why?
|
| Obesity | 3 | 2023 | 356 | 0.210 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2022 | 2 | 0.210 |
Why?
|
| Paraproteinemias | 1 | 2022 | 2 | 0.210 |
Why?
|
| Health Services Accessibility | 4 | 2024 | 265 | 0.210 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2023 | 190 | 0.210 |
Why?
|
| Multiple Myeloma | 1 | 2022 | 12 | 0.210 |
Why?
|
| Lipoproteins, HDL | 1 | 2022 | 9 | 0.210 |
Why?
|
| Glucose | 1 | 2022 | 45 | 0.210 |
Why?
|
| Cholesterol | 1 | 2022 | 38 | 0.210 |
Why?
|
| Prognosis | 5 | 2023 | 197 | 0.200 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2024 | 113 | 0.200 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2023 | 19 | 0.200 |
Why?
|
| Death | 2 | 2019 | 14 | 0.200 |
Why?
|
| Malignant Hyperthermia | 2 | 1992 | 2 | 0.190 |
Why?
|
| Obesity, Abdominal | 1 | 2021 | 19 | 0.190 |
Why?
|
| Breast | 2 | 2021 | 10 | 0.190 |
Why?
|
| Mitotic Index | 1 | 2021 | 1 | 0.190 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2021 | 16 | 0.180 |
Why?
|
| Delphi Technique | 1 | 2021 | 28 | 0.180 |
Why?
|
| Africa South of the Sahara | 4 | 2024 | 328 | 0.180 |
Why?
|
| Consensus | 1 | 2021 | 59 | 0.180 |
Why?
|
| Caregivers | 2 | 2019 | 66 | 0.180 |
Why?
|
| Urban Health | 1 | 2021 | 78 | 0.180 |
Why?
|
| Young Adult | 4 | 2020 | 2357 | 0.180 |
Why?
|
| Cancer Survivors | 1 | 2020 | 3 | 0.170 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 61 | 0.170 |
Why?
|
| Quality of Health Care | 1 | 2019 | 58 | 0.160 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 14 | 0.160 |
Why?
|
| Comorbidity | 4 | 2020 | 184 | 0.160 |
Why?
|
| Patient Preference | 1 | 2018 | 22 | 0.150 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 42 | 0.150 |
Why?
|
| Mastectomy, Segmental | 1 | 2017 | 3 | 0.150 |
Why?
|
| Proportional Hazards Models | 3 | 2022 | 163 | 0.140 |
Why?
|
| Cost of Illness | 1 | 2018 | 155 | 0.140 |
Why?
|
| Age Factors | 4 | 2019 | 364 | 0.130 |
Why?
|
| Genotype | 3 | 2023 | 430 | 0.130 |
Why?
|
| Odds Ratio | 3 | 2021 | 132 | 0.120 |
Why?
|
| Muscles | 2 | 1992 | 3 | 0.120 |
Why?
|
| Travel | 1 | 2014 | 21 | 0.110 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2023 | 7 | 0.110 |
Why?
|
| Tamoxifen | 2 | 2023 | 9 | 0.110 |
Why?
|
| Biomarkers, Tumor | 2 | 2023 | 25 | 0.110 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 1377 | 0.110 |
Why?
|
| Survival Analysis | 2 | 2024 | 149 | 0.100 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 367 | 0.100 |
Why?
|
| Muscle Proteins | 1 | 1991 | 2 | 0.090 |
Why?
|
| Protein Kinases | 1 | 1991 | 4 | 0.090 |
Why?
|
| United States | 2 | 2021 | 129 | 0.090 |
Why?
|
| HIV Seropositivity | 1 | 2013 | 263 | 0.090 |
Why?
|
| Anti-HIV Agents | 1 | 2018 | 1275 | 0.090 |
Why?
|
| Adolescent | 3 | 2022 | 2858 | 0.080 |
Why?
|
| Delayed Diagnosis | 2 | 2020 | 15 | 0.080 |
Why?
|
| Survival Rate | 2 | 2020 | 96 | 0.080 |
Why?
|
| Prostate | 2 | 2018 | 4 | 0.080 |
Why?
|
| Incidence | 2 | 2021 | 655 | 0.070 |
Why?
|
| Logistic Models | 2 | 2019 | 252 | 0.070 |
Why?
|
| Viral Load | 2 | 2022 | 808 | 0.070 |
Why?
|
| Neoplasm Grading | 2 | 2018 | 15 | 0.070 |
Why?
|
| Population Groups | 2 | 2017 | 9 | 0.060 |
Why?
|
| Socioeconomic Factors | 2 | 2019 | 405 | 0.060 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2024 | 1 | 0.060 |
Why?
|
| Genetic Markers | 1 | 2024 | 11 | 0.060 |
Why?
|
| DNA Methylation | 1 | 2024 | 19 | 0.060 |
Why?
|
| Vaginal Smears | 1 | 2024 | 34 | 0.060 |
Why?
|
| Papillomaviridae | 1 | 2024 | 33 | 0.060 |
Why?
|
| Filgrastim | 1 | 2023 | 4 | 0.060 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2023 | 2 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 16 | 0.050 |
Why?
|
| Macrophages | 1 | 2023 | 15 | 0.050 |
Why?
|
| RNA | 1 | 2023 | 26 | 0.050 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2022 | 8 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2023 | 96 | 0.050 |
Why?
|
| Diet Surveys | 1 | 2021 | 7 | 0.050 |
Why?
|
| Waist-Hip Ratio | 1 | 2021 | 22 | 0.050 |
Why?
|
| Principal Component Analysis | 1 | 2021 | 20 | 0.050 |
Why?
|
| Waist Circumference | 1 | 2021 | 53 | 0.050 |
Why?
|
| Disease-Free Survival | 1 | 2021 | 25 | 0.050 |
Why?
|
| Reproductive History | 1 | 2021 | 2 | 0.050 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2021 | 8 | 0.050 |
Why?
|
| Research Report | 1 | 2021 | 11 | 0.050 |
Why?
|
| Menopause | 1 | 2021 | 24 | 0.050 |
Why?
|
| Life Style | 1 | 2021 | 80 | 0.040 |
Why?
|
| Genetic Loci | 1 | 2020 | 11 | 0.040 |
Why?
|
| Spirituality | 1 | 2020 | 11 | 0.040 |
Why?
|
| Rural Population | 1 | 2024 | 624 | 0.040 |
Why?
|
| HIV | 1 | 2023 | 380 | 0.040 |
Why?
|
| Genetics, Population | 1 | 2020 | 50 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2021 | 312 | 0.040 |
Why?
|
| Stress, Psychological | 1 | 2020 | 25 | 0.040 |
Why?
|
| Pain | 1 | 2020 | 40 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2020 | 26 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 18 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 532 | 0.040 |
Why?
|
| Matched-Pair Analysis | 1 | 2019 | 2 | 0.040 |
Why?
|
| Social Support | 1 | 2020 | 76 | 0.040 |
Why?
|
| Self Report | 1 | 2019 | 111 | 0.040 |
Why?
|
| Meat | 1 | 2019 | 3 | 0.040 |
Why?
|
| Fruit | 1 | 2019 | 5 | 0.040 |
Why?
|
| Attitude to Death | 1 | 2019 | 6 | 0.040 |
Why?
|
| Vegetables | 1 | 2019 | 8 | 0.040 |
Why?
|
| Premenopause | 1 | 2019 | 14 | 0.040 |
Why?
|
| Epirubicin | 1 | 2018 | 2 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2018 | 5 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2018 | 8 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2018 | 19 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2019 | 217 | 0.040 |
Why?
|
| Baltimore | 1 | 2018 | 5 | 0.040 |
Why?
|
| Age Distribution | 1 | 2018 | 106 | 0.040 |
Why?
|
| Home Nursing | 1 | 2018 | 8 | 0.040 |
Why?
|
| Animals | 2 | 1992 | 1063 | 0.040 |
Why?
|
| Quality of Life | 1 | 2020 | 170 | 0.040 |
Why?
|
| Income | 1 | 2018 | 83 | 0.040 |
Why?
|
| Emotions | 1 | 2018 | 18 | 0.040 |
Why?
|
| Genomics | 1 | 2018 | 106 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2017 | 55 | 0.040 |
Why?
|
| Africa | 1 | 2017 | 360 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2018 | 654 | 0.030 |
Why?
|
| Hospitalization | 1 | 2018 | 392 | 0.030 |
Why?
|
| Pregnancy | 1 | 2021 | 1815 | 0.030 |
Why?
|
| HIV Seronegativity | 1 | 2013 | 52 | 0.030 |
Why?
|
| Breast Neoplasms, Male | 1 | 2013 | 1 | 0.030 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2013 | 1 | 0.030 |
Why?
|
| SEER Program | 1 | 2013 | 2 | 0.030 |
Why?
|
| Electrophysiology | 1 | 1992 | 1 | 0.030 |
Why?
|
| Receptors, Cholinergic | 1 | 1992 | 1 | 0.030 |
Why?
|
| Receptors, Nicotinic | 1 | 1992 | 1 | 0.030 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 1 | 1992 | 1 | 0.030 |
Why?
|
| Calcium Channels | 1 | 1992 | 6 | 0.030 |
Why?
|
| Genetic Linkage | 1 | 1992 | 8 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 1992 | 9 | 0.030 |
Why?
|
| Time Factors | 1 | 2013 | 503 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 1991 | 1 | 0.020 |
Why?
|
| Muscle Contraction | 1 | 1991 | 5 | 0.020 |
Why?
|
| Phosphorylation | 1 | 1991 | 6 | 0.020 |
Why?
|
| Molecular Weight | 1 | 1991 | 13 | 0.020 |
Why?
|
| Cytosol | 1 | 1991 | 9 | 0.020 |
Why?
|
| Swine | 1 | 1991 | 49 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 1991 | 54 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 1991 | 34 | 0.020 |
Why?
|